Eckert & Ziegler to supply Lutetium-177 to Alpha-9 Theranostics for clinical trials

Eckert & Ziegler has signed a clinical supply agreement with Alpha-9 Theranostics to supply its medical radioisotope Lutetium-177 (n.c.a. 177Lu) for the clinical development of Alpha-9's investigational drugs for solid and hematologic malignancies.

“Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler’s medical radioisotope Lutetium-177 (non-carrier-added 177Lu).”a9oncology.com

• 1 source
• a9oncology.comEckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials - Alpha-9 OncologyraincastleMar 23, 2022

Summarized from public sources; check the original articles before acting on it.